Dupont Nutrition Biosciences Aps

Finfeeds International Limited

Danisco A/s

Suomen Rehu Oy

Nina Rautonen

Kirsti Tiihonen

Arthur Ouwehand

Heli Putaala

Rodolphe Barrangou

Sampo Lahtinen

Rémy Burcelin

Didier Carcano

Pierre Desreumaux

Seppo Salminen

Juhani Vuorenmaa

Erika Isolauri

Michael Richard Bedford

Juha H Apajalahti

Heli Anglenius

Marta Korczynska

Wouter Herman Noordman

Juha Apajalahti

Marta Zdzislawa Korczynska

Seppo Jaakko Salminen

The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.

Probiotic bacteria for the topical treatment of skin disorders

The invention relates to use of a bacterium selected from a lactic acid bacterium, aor a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.

Lactic acid bacteria andfor treating endotoxemia

Lactic acid bacteria and bifidobacteria for treating endotoxemia

The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms. Suitably, such compositions may compriseor both.

Probiotics for use in reducing eosinophilia and respiratory allergies

Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain ofspp. and/orspp., for example a strain ofand/or

[object Object]

The present invention relates to the use of a combination of a protease and an inner salt of a quaternary amine carboxylic acid for the preparation of an agent for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities in animals. Preferred embodiments of the invention comprise the inclusion of a xylanase and/or an &#x3b1;-amylase in the agent. A nutritional additive comprising a combination of an inner salt of a quaternary amine carboxylic acid protease and (optionally) a xylanase and an &#x3b1;-amylase is also disclosed. It can be used for improving the rate of weight gain of animals.

Additive for an animal feed

Growing community of inventors

Espoo, Finland

Nina Rautonen